The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Tuati H.

Peoples’ Friendship University of Russia, Moscow, Russia, 117198

Tishchenko A.L.

Rossiĭskiĭ universitet druzhby narodov, Moskva

Gorskiĭ V.S.

GUZ Tul'skiĭ oblastnoĭ kozhno-venerologicheskiĭ dispanser

Pharmacotherapy of acne: an overview of current therapies

Authors:

Tuati H., Tishchenko A.L., Gorskiĭ V.S.

More about the authors

Read: 26010 times


To cite this article:

Tuati H, Tishchenko AL, Gorskiĭ VS. Pharmacotherapy of acne: an overview of current therapies. Russian Journal of Clinical Dermatology and Venereology. 2018;17(2):11‑16. (In Russ.)
https://doi.org/10.17116/klinderma201817211-16

Recommended articles:
Clinical features of severe acne and gene­tic dete­rminants of therapeutic effi­cacy of systemic isotretinoin. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):30-37
Study of the role of inte­rleukin-1β in blood serum in patients with acne. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):421-424
Adhe­rence of patients to acne therapy using systemic isotretinoin. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):483-488
Clinical discussion of patients with follicular occlusion syndrome and como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):596-603
Rational choice of combined therapy of acne: systemic isotretinoin and high-energy hardware technologies. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):651-656
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130

References:

  1. Nast A, Dreno B, Bettoli V. European Evidence-based (S3) Guidelines for the Treatment of Acne. JEADV 2012;26(Suppl. 1):1-29.
  2. Kungurov NV, Zil’berberg NV, Tolstaja AI, Kohan MM. Pathogenetic basis and clinical efficiency of combined therapy of patients with acne and post-acne. Lech vrach. 2013;(10):24-28 (In Russ.)
  3. Magin P, Adams J, Heading G, Pond D. ‘Perfect skin’, the media and patients with skin disease: a qualitative study of patients with acne, psoriasis and atopic eczema. Aust J Prim Health. 2011;17:181-185.
  4. Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol. 2008;59(4):659-676.
  5. Beylot C, Auffret N, Poli E, Claudel J-P, Leccia MT. Propionobacterium acnes: an update on its role in the pathogenesis of acne. JEADV. 2014;28:271-278.
  6. Aravijskaja ER, Sokolovskij EV. Systemic antibiotic therapy of acne: some controversial issues. Vestn dermatol venerol. 2013;(6):117-121 (In Russ.)
  7. Rottboel L, de Foenss S, Thomsen K, Christiansen H, Andersen SM. Exploring valrubicin’s effect on Propionobacterium acnes-induced skin inflammation in vitro and in vivo. Dermatol Rep. 2015;7:6246.
  8. Suh DH, Kwon HH. What’s new in the physiopathology of acne. Br J Dermatol. 2015;172(Suppl. 1):13-19.
  9. Khayef G, Young J, Burns-Whitmore B, Spalding T. Effects of fish oil supplementation on inflammatory acne. Lipids in health and disease. 2012;11:165.
  10. Lai JJ, Chang P, Lai KP, Chen L, Chang C. The role of androgen and androgen receptor in the skin-related disorders. Arch Dermatol Res. 2012;304:499-510.
  11. Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012;86(8):734-740.
  12. Thiboutot D, Dreno B, Gollnick H. A call to limit antibiotic use in acne. J Drugs Dermatol. 2013;12:1331-1332.
  13. Perlamutrov YuN, Chizhova SK, Korchevaja TA, Ol’hovskaja KB. Comparative efficacy and tolerability of different methods of acne treatment in women. Klinicheskaya dermatologiya i venerologiya. 2012;(3): 72-77. (In Russ.)
  14. Aravijskaja ER, Sokolovskij EV. A combination of drugs in the external treatment of acne: current data. Vestn dermatol venerol. 2012;(3):111-114. (In Russ.)
  15. Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013;79:322-337.
  16. Hussein-El Ahmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015;28(3):166-172.
  17. Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5:201-213.
  18. Lam C, Zaenglein AL. Contraceptive use in acne. Clin Dermatol. 2014;32:502-515.
  19. Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinical-based on current data and clinical experience. J Clin Aesthet Dermatol. 2012;5:37-50.
  20. Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in hirsute woman with polycystic ovary syndrome. J Reprod Med. 2014;59:455-463.
  21. Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young woman taking spironolactone for acne. JAMA Dermatol. 2015;151:941-944.
  22. Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M. Comparison of desogestrel/ethinylestradiol plus spironolactone versus cyproterone acetate/ethinylestradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res. 2015;41:401-410.
  23. Saint-Jean M, Ballanger F, Nguyen JM, Khammari A, Dreno B. Importance of spironolactone in the treatment of acne in adult woman. J Eur Acad Dermatol Venereol. 2011;25:1480-1481.
  24. Arowojolu AO, Gallo MF, Lopez LM, Grimez DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.
  25. Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H. Flutamide versus a cyproterone acetate-ethynil estradiol combination in moderate acne: a pilot randomized clinical trial. Clin Cosmet Investig Dermatol. 2011;4:117-121.
  26. Friedman. Spironolactone for adult female acne. Cutis. 2015;96:216-217.
  27. Zaenglein AL, Pathy AL, Schlosser BJ. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
  28. Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015;172(Suppl. 1):37-46.
  29. Del Rosso JQ, Harper JC, Graber EM, Thiboutot D, Silverberg NB. Status report from the American Acne&Rosacea Society on medical management of acne in adult woman, part1: overview, clinical characteristics, and laboratory evaluation. Cutis. 2015;96:236-241.
  30. Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30:1480-1490.
  31. Nast A, Ernst H, Rosumeck S, Erdmann R, Jacobs A. Risk of complications due to anticoagulation during dermatosurgical procedures: a systematic review and metaanalysis. J Eur Acad Dermatol Venereol. 2014;28(12): 1603-1609.
  32. Zaba R, Shwartz R, Jarmuda S, Czarnecka-Operatz M, Silny W. Acne fulminans: explosive systemic form of acne. J Eur Acad Dermatol Venerol. 2011;25:501-507.
  33. Tago O, Nagai Y, Matsushima Y, Ishikawa O. A case of acne fulminans successfully treated with cyclosporine A and prednisolone. Acta Derm Venerol. 2011;91:337-338.
  34. Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 2013;68(4):663-671.
  35. Gollnick HP, Dreno B. Pathophysiology and management of acne. J Eur Acad Dermatol Venereol. 2015;29(Suppl. 4):1-2.
  36. Harper JC. Use of oral contraceptives for management of acne vulgaris: practical considerations in real world practice. Dermatol Clin. 2016;34(2):159-165.
  37. Arrington EA, Patel NS, Geranker A, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012;90(2):83-90.
  38. Chularojanamontri L, Tuchinda P, Kulthanan K, Pongparit K. Moisturizers for Acne: What are their Constituents? J Clin Aesthet Dermatol. 2014;7:37-44.
  39. Ghosh S, Chauduri S, Jain VK, Aggarwal K. Profiling and hormonal therapy for acne in woman. Indian J Dermatol. 2014;59(2):107-115.
  40. Bubna AK. Metformin — for the dermatologist. Indian J Pharmacol. 2016;48(1):4-40.
  41. Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. Dermatol Ther. 2013;26:302-311.
  42. Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin-a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-1062.
  43. Del Rosso JQ, Webster GF, Rosen T, Thiboutot D, Leyden JJ. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1. Antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use. J Clin Aesthet Dermatol. 2016;9:18-24.
  44. Amichai B, Grunwald MH. Isotretinoin in dermatology. J Dermatol Treat. 2002;11:219-240.
  45. Olisova OYu. The effectiveness of systemic retinoids for acne. RMZh. 2016;(10):602-606 (In Russ.)
  46. Dolzhikova JeM, Sternin YuI, Shuginina EA. Pathogenetic rationale and experience of using systemic enzyme therapy in cosmetology and plastic surgery. RMZh. 2011;(11):19:698-702. (In Russ.)
  47. Vil’son S, Tishchenko AL, Gorskii VS. Assessment of the ability of lymphocytes to activate background local injections of acidic peptidoglycan in patients with acne. Klinicheskaya dermatologiya i venerologiya. 2015;(3):14:37-39 (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.